Eiger BioPharmaceuticals Stock Forecast, Price & News

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EIGR shares have increased by 33.0% and is now trading at $9.06.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eiger BioPharmaceuticals.

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.09.
View Eiger BioPharmaceuticals' earnings history.

3 equities research analysts have issued 1 year target prices for Eiger BioPharmaceuticals' shares. Their forecasts range from $28.00 to $32.00. On average, they expect Eiger BioPharmaceuticals' stock price to reach $30.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals.

Some companies that are related to Eiger BioPharmaceuticals include Black Diamond Therapeutics (BDTX), Vericel (VCEL), Alector (ALEC), Inhibrx (INBX), Cellectis (CLLS), Compugen (CGEN), TCR2 Therapeutics (TCRR), Krystal Biotech (KRYS), NantKwest (NK), Taysha Gene Therapies (TSHA), Vaxart (VXRT), BioCryst Pharmaceuticals (BCRX), Passage Bio (PASG), Poseida Therapeutics (PSTX) and Agenus (AGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.68%), Mangrove Partners (3.36%), Assenagon Asset Management S.A. (1.90%), State Street Corp (1.58%), P.A.W. Capital Corp (1.23%) and DAVENPORT & Co LLC (0.79%). Company insiders that own Eiger BioPharmaceuticals stock include David A Cory, Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals.

EIGR stock was sold by a variety of institutional investors in the last quarter, including Voss Capital LLC, JPMorgan Chase & Co., Connor Clark & Lunn Investment Management Ltd., Arrowstreet Capital Limited Partnership, Rock Creek Group LP, AQR Capital Management LLC, Morgan Stanley, and DAVENPORT & Co LLC.
View insider buying and selling activity for Eiger BioPharmaceuticals.

EIGR stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., BlackRock Inc., Mangrove Partners, GSA Capital Partners LLP, P.A.W. Capital Corp, Towerview LLC, Massachusetts Financial Services Co. MA, and Zeke Capital Advisors LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals.

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EIGR stock can currently be purchased for approximately $9.06.

Eiger BioPharmaceuticals has a market capitalization of $294.74 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger BioPharmaceuticals employs 28 workers across the globe.

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]